208457-46-9

Basic information

• Product Name: 1,2-Benzenedicarboxylic acid, 4-bromo-, 1-methyl ester
• CAS NO: 208457-46-9
• Molecular Formula: C9H7BrO4
• Molecular Weight: 259.056
• Mol File: 208457-46-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1,2-Benzenedicarboxylic acid, 4-bromo-, 1-methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Benzenedicarboxylic acid, 4-bromo-, 1-methyl ester(208457-46-9)
• EPA Substance Registry System: 1,2-Benzenedicarboxylic acid, 4-bromo-, 1-methyl ester(208457-46-9)

Safety Data

• Hazardous Substances Data: 208457-46-9(Hazardous Substances Data)

Upstream product

• 75-77-4 chloro-trimethyl-silane 
• 6968-28-1 4-bromophthalic acid 
• 85-44-9 phthalic anhydride 
• 86-90-8 4-bromophthalic anhydride 

Relevant articles and documents

Synthesis and biological evaluation of chemokine receptor ligands with 2-benzazepine scaffold

Targeting CCR2 and CCR5 receptors is considered as promising concept for the development of novel antiinflammatory drugs. Herein, we present the development of the first probe-dependent positive allosteric modulator (PAM) of CCR5 receptors with a 2-benzazepine scaffold. Compound 14 (2-isobutyl-N-({[N-methyl-N-(tetrahydro-2H-pyran-4-yl)amino]methyl}phenyl)-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxamide) activates the CCR5 receptor in a CCL4-dependent manner, but does not compete with [3H]TAK-779 binding at the CCR5. Furthermore, introduction of a p-tolyl moiety at 7-position of the 2-benzazepine scaffold turns the CCR5 PAM 14 into the selective CCR2 receptor antagonist 26b. The structure affinity and activity relationships presented here offer new insights into ligand recognition by CCR2 and CCR5 receptors.

HETERO-BIARYL-PYRIDOQUINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS

The invention provides a compound having the formula (1), wherein (A) n = 2-4; (B) R1 and R2 are the same or different and selected from the group consisting of H, (C1-C3) alkyl, -CH2CH2OH, -CH2CH2NH2, and -CH2CH2N(CH3)2 or R1 and R2 are alkyl moieties which are taken together to form a 4- to 7-membered ring; (C) R3 is selected from the group consisting of H, -CH3, -CH2CH3, and -CH2CH2NH2; (D) Y is a heterocyclic radical having 5-14 atoms, located at the 2- or 3-position of the pyridoquinazolinone nucleus, in which 1-3 of the heterocyclic ring atoms are independently nitrogen, oxygen, or sulfur; wherein Y may be optionally mono-, di-, or tri-substituted with -OR4, -NR5R6, -CO2H, -CO2R4, or phenyl; R4 is H or (C1-C4) straight-chain alkyl; R5 and R6 are the same or different and are selected from the group consisting of H, (C1-C4) straight-chain alkyl, -CH2CH2OH, -CH2CH2NH2, and -CH2CH2N(CH3)2 or R5 and R6 are alkyl moieties which are taken together to form a 4-7 membered ring; or a pharmaceutically acceptable salt thereof which is useful as an antineoplastic agent.